The Importance of a Manufacturing Strategy: Lessons Learned with Steve Lam
For some companies, bioprocessing is a well-oiled machine. For others, it’s a car crash capable of derailing a product launch by months.
Stephanie Sutton |
Commercial-scale bioprocessing is an art. Successful biopharma companies have perfected it through repetition and the implementation of new biopharma technologies. And so, manufacturing can be considered ‘easy’ compared with the trials and tribulations of drug discovery and clinical trials, particularly when product development follows well-established methodologies and a well thought-out manufacturing strategy. According to Steve Lam, Senior Vice President of Patheon’s Biologics Business, considering your manufacturing strategy early on in development pays dividends down the line – and yet it is something that many small (and large) companies fail to do. Here, Lam recounts the lessons he has learned over almost three decades in biopharma.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.